752242-47-0

Upstream product

• 752242-45-8 3-hydroxy-5-(4-methanesulfonylphenoxy)benzoic acid methyl ester 
• 136918-07-5 (2R)-1[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-propanol 
• 54915-31-0 methyl 3-(benzyloxy)-5-hydroxybenzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 871656-49-4 methyl 3-(benzyloxy)-5-(4-(methylsulfonyl)phenoxy)benzoate 

Downstream Products

• 871656-50-7 3-[(1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethoxy]-N-[4-(methoxymethyl)-1,3-thiazol-2-yl]-5-[4-(methylsulfonyl)phenoxy]benzamide 
• 871656-48-3 3-((1S)-2-{[tert-butyl(dimethyl)silyl]oxy}-1-methylethoxy)-5-[4-(methylsulfonyl)phenoxy]-benzoic acid 

Relevant academic research and scientific papers

HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES

Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-linked optionally substituted heterocyclyl ring; R3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R4 is selected from for example hydrogen, optionally substituted (1-4C)alkyl and HET-2; R5 is hydrogen or (1-4C)alkyl; or R4 and R5 together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3; HET-3 is for example an optionally substituted N-linked, 4, 5 or 6 membered, saturated or partially unsaturated heterocyclyl ring; p is (independently at each occurrence) 0, 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, then n is 1 or 2; or a salt, pro drug or solvate thereof, are described. Their use as GLK activators, pharmaceutical compositions containing them, and processes for their preparation are also described.

HETEROARYLCARBAMOYLBENZENE DERIVATIVE

Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein X1 represents oxygen, etc., X2 represents oxygen, etc., R1 represents a group on Ring A such as alkylsulfonyl, etc., R2 represents C3-7 cyclic alkyl optionally substituted with a halogen, etc., R3 represents a substituent on Ring B such as lower alkyl, etc., formula (II): represents 6- to 10-membered aryl, etc., and formula (III): represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by R3 above, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C=N bond with the nitrogen atom of the ring], as well as their pharmaceutically acceptable salts.